Michael J Haller
Overview
Explore the profile of Michael J Haller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
3464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Phillip M, Achenbach P, Addala A, Albanese-ONeill A, Battelino T, Bell K, et al.
Diabetes Care
. 2024 Sep;
47(11):2033.
PMID: 39240700
No abstract available.
12.
Phillip M, Achenbach P, Addala A, Albanese-ONeill A, Battelino T, Bell K, et al.
Diabetologia
. 2024 Sep;
67(9):2012-2014.
PMID: 39230637
No abstract available.
13.
Maizel J, Filipp S, Zori G, Yadav S, Avaiya K, Figg L, et al.
J Contin Educ Health Prof
. 2024 Aug;
PMID: 39162718
Introduction: Since its inception in 2003, the Project Extension for Community Healthcare Outcomes (ECHO) tele-education model has reached and improved outcomes for patients, providers, and health centers through interventions in...
14.
Jonsdottir B, Clasen J, Vehik K, Lernmark A, Lundgren M, Bonifacio E, et al.
J Clin Endocrinol Metab
. 2024 Jul;
110(2):498-510.
PMID: 38996042
Context: Autoantibodies to thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) define preclinical autoimmune thyroid disease (AITD), which can progress to either clinical hypothyroidism or hyperthyroidism. Objective: We determined the age at...
15.
Morales J, Klose M, Hoffert Y, Podichetty J, Burton J, Schmidt S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Jul;
13(8):1309-1316.
PMID: 38961520
Clinical trials seeking to delay or prevent the onset of type 1 diabetes (T1D) face a series of pragmatic challenges. Despite more than 100 years since the discovery of insulin,...
16.
Phillip M, Achenbach P, Addala A, Albanese-ONeill A, Battelino T, Bell K, et al.
Diabetes Care
. 2024 Jun;
47(8):1276-1298.
PMID: 38912694
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease...
17.
Phillip M, Achenbach P, Addala A, Albanese-ONeill A, Battelino T, Bell K, et al.
Diabetologia
. 2024 Jun;
67(9):1731-1759.
PMID: 38910151
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease...
18.
Warncke K, Tamura R, Schatz D, Veijola R, Steck A, Akolkar B, et al.
J Endocr Soc
. 2024 Jun;
8(7):bvae103.
PMID: 38867880
Context: The 2 peaks of type 1 diabetes incidence occur during early childhood and puberty. Objective: We sought to better understand the relationship between puberty, islet autoimmunity, and type 1...
19.
Mehta S, Ryabets-Lienhard A, Patel N, Breidbart E, Libman I, Haller M, et al.
Horm Res Paediatr
. 2024 Apr;
:1-12.
PMID: 38663372
Teplizumab (TzieldTM, Provention Bio), a monoclonal antibody directed at T-cell marker CD3, is the first medication approved by the FDA to delay progression from stage 2 to stage 3 type...
20.
Jacobsen L, Cuthbertson D, Bundy B, Atkinson M, Moore W, Haller M, et al.
Diabetes Care
. 2024 Apr;
47(6):1048-1055.
PMID: 38621411
Objective: Mixed-meal tolerance test-stimulated area under the curve (AUC) C-peptide at 12-24 months represents the primary end point for nearly all intervention trials seeking to preserve β-cell function in recent-onset...